Inspira Technologies Oxy B.H.N. (IINN)
Builds AME quantum-connectivity hardware while advancing respiratory support and blood-monitoring devices.
Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Shares Up 24.8% – Time to Buy?
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN - Get Free Report) rose 24.8% on Thursday. The stock traded as high as $1.35 and last traded at $1.12. 27,826,361 shares changed hands during mid-day trading, an increase of 7,795% from the average session volume of 352,435 shares. The stock had previously closed at $0.8975. Inspira Technologies
QTREX Announces Pricing of a $10 Million Registered Direct Offering of Ordinary Shares
QTREX Quantum Ltd. announced the pricing of a $10 million registered direct offering of 11,111,111 ordinary shares priced at-the-market under Nasdaq rules.
Inspira Technologies OXY B.H.N. (IINN) to Post Earnings on Thursday
Inspira Technologies OXY B.H.N. (NASDAQ: IINN - Get Free Report) is expected to post its results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $15.00 million for the quarter. Inspira Technologies OXY B.H.N. Trading Up 12.2% Shares of NASDAQ: IINN opened at $1.01
NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
RA'ANANA, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company") today announced that it has received a $580,000 commercial purchase order from NYU Langone Hospital in New York City (“NYU Langone”) for the Company's FDA-cleared ART100 extracorporeal blood circulation systems. The order was placed through Inspira's U.S. distributor following the successful completion of a multi-patient clinical evaluation at the hospital, and the systems are scheduled for immediate fulfillment. This commercial milestone is in parallel with the Company's previously disclosed active strategic process involving the ART100 platform and broader medical assets.
Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan
RA'ANANA, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," "Inspira Technologies," or the "Company"), today issued a letter to its shareholders from its Chief Executive Officer, Dagi Ben-Noon.
Inspira Secures $596,000 AME System Order from Leading Irish Technological University
RA'ANANA, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company") today announced that it has secured a $596,000 purchase order for an Additively Manufactured Electronics ("AME") system from a leading Irish technological research university. The order is structured with a non-refundable upfront payment of 40% of the order value, which has been received by the Company, with the balance payable against delivery.
Inspira Technologies (IINN) Falls After-Hours — What's Going On?
Inspira stock falls after-hours despite AME system deployment at U.S. defense customer, highlighting commercial expansion efforts.
Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase
RA'ANANA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the termination of its sales agreement with A.G.P./Alliance Global Partners, dated February 17, 2026, and its Standby Equity Purchase Agreement with YA II PN, Ltd, dated December 12, 2025.
Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates
Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale
Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks
RA'ANANA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies,” “Inspira,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic commercial showcase of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system. The system will be featured at the American Society of Extracorporeal Technology (AmSECT) 64th International Conference, taking place March 25–29, 2026, in Austin, Texas, at the exhibition booth of its U.S. distributor, Glo-Med Networks Inc. (“Glo-Med”).
Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market
Company's validation confirms 94.2% accuracy for blood pCO₂ measurement, pivot to standalone configuration opens immediate commercial pathway to global installed base of heart-lung machines and extracorporeal procedures Company's validation confirms 94.2% accuracy for blood pCO₂ measurement, pivot to standalone configuration opens immediate commercial pathway to global installed base of heart-lung machines and extracorporeal procedures
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders
RA'ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant progress in the execution of its previously announced binding purchase orders.
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholders of Inspira relating to its existing technologies All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholders of Inspira relating to its existing technologies
Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholders of Inspira relating to its existing technologies All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protections for existing shareholders of Inspira relating to its existing technologies
Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones
Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026 Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026
Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution
RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with YA II PN, Ltd. (“YA”) for a registered direct offering of its ordinary shares, and has also entered into a Standby Equity Purchase Agreement (“SEPA”) with YA providing additional equity financing flexibility.
Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology
RA'ANANA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of its core blood laboratory capabilities, marking a substantial step in the Company's evolution into a broader cutting edge technologies, positioning it for accelerated future growth.
Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission
RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the completion of the clinical study for its HYLA, non-invasive blood sensor, toward regulatory submission and future commercialization.
Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion
RA'ANANA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has completed the regulatory submission of its FDA-cleared INSPIRA™ ART100 system (“ART100”) to the United Arab Emirates Ministry of Health and Prevention (“MOHAP”). Final approval is expected within days, marking a decisive step toward commercial entry into the Gulf region.
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Inspira delivered major milestones throughout and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation in leading hospitals, 97.35% accuracy for its HYLA blood sensor, and strategic patent protection, underscoring accelerating commercial momentum. Inspira delivered major milestones throughout and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation in leading hospitals, 97.35% accuracy for its HYLA blood sensor, and strategic patent protection, underscoring accelerating commercial momentum.